放射性皮膚炎市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Radiodermatitis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年04月28日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024年，全球放射性皮膚炎市場規模達4.674億美元，預計到2034年將以4.3%的複合年成長率成長，達到7.1億美元。放射性皮膚炎是接受放射治療的癌症患者常見的副作用，通常表現為局部皮膚變化，會嚴重影響患者的舒適度和生活品質。這種疾病是由累積輻射暴露引起的，輻射會損害皮膚的基底細胞層，削弱其再生能力，並引發發炎反應。隨著腫瘤治療技術的進步和放射技術的精準化，由於輻射劑量集中，放射性皮膚炎的發生率和可見度仍然很高。

對此，醫療保健提供者和製藥公司都在強調預防和治療介入的重要性。以患者為中心的癌症治療日益受到重視，這加劇了對局部治療、先進傷口護理產品以及旨在減輕放射治療引起的皮膚損傷的臨床指南的需求。隨著醫療保健系統優先考慮腫瘤的整體治療方法，改善患者舒適度和最大程度減少治療相關副作用的重要性比以往任何時候都更加突出。這種以患者為中心的癌症治療的轉變正在推動對專門針對放射性皮膚炎的專用外用藥物和先進傷口護理技術的研發投入。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	4.674億美元
預測值	7.1億美元
複合年成長率	4.3%

市場主要分為兩大類：外用藥物和敷料。 2024年，外用藥物佔了66.5%的市場。外用製劑研發的進步，例如強化傷口照護產品和更有效的給藥系統，正在拓展患者的治療選擇。這些創新，加上癌症治療中對安寧療護的日益重視，增加了對緩解放射性皮膚炎症狀的外用藥物的需求。

放射性皮膚炎治療的分銷也是市場成長的重要因素。 2024年，醫院藥局市場規模達2.4億美元。接受放射治療的癌症患者數量不斷增加，導致這些機構對放射性皮膚炎管理產品的需求不斷增加。醫院藥房與腫瘤科的整合確保患者能夠及時便捷地獲得治療，從而進一步支持市場成長。

預計到2034年，美國放射性皮膚炎市場規模將達到2.86億美元。美國癌症診斷率很高，其中很大一部分患者接受放射治療。因此，美國對有效治療放射性皮膚炎的療法的需求日益成長。採用支持性治療方案以及日益重視皮膚反應管理推動了此類療法的需求。全國各地的醫院和癌症中心都更加重視全面的支持性治療，包括放射性皮膚病的早期介入。

全球放射性皮膚炎市場的主要參與者包括康樂保 (Coloplast)、Integra Lifesciences Corporation、強生 (Johnson & Johnson)、B. Braun Melsungen 和全錄輝 (Smith & Nephew) 等大型公司。這些公司正在投資創新產品，以滿足日益成長的有效治療需求。他們還透過與醫療保健提供者合作並拓展分銷管道來增強市場影響力，以確保產品覆蓋更廣泛的患者群體。為了在放射性皮膚炎市場保持競爭力，各公司專注於策略合作夥伴關係、產品創新和擴大全球影響力。許多組織正在投資研發，以提高現有治療方法的療效，並為放射性皮膚炎管理創造新的、更有效的解決方案。

產業生態系統分析
產業衝擊力
- 成長動力
  - 癌症發生率和放射治療使用率不斷上升
  - 放射治療期間皮膚護理意識的提高
  - 放射性皮膚炎產品的進展
  - 有利的政府措施和指導方針
- 產業陷阱與挑戰
  - 先進治療方案成本高昂
  - 缺乏標準化的治療指南
成長潛力分析
監管格局
技術格局
未來市場趨勢
差距分析
波特的分析
PESTEL分析

第4章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
策略儀表板

第5章：市場估計與預測：依產品類型，2021 年至 2034 年

主要趨勢
外用藥物
- 皮質類固醇
- 抗生素
- 乳霜
- 其他外用藥物
敷料
- 水凝膠敷料
- 水膠體敷料
- 泡棉敷料
- 阻隔膜
- 其他敷料

第6章：市場估計與預測：按配銷通路，2021 年至 2034 年

主要趨勢
醫院藥房
零售藥局
電子商務

第7章：市場估計與預測：按地區，2021 年至 2034 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第8章：公司簡介

Alliqua BioMedical
B. Braun Melsungen
Bayer
BMG Pharma
Coloplast
ConvaTec Group
Integra LifeSciences Corporation
Intermed
Johnson & Johnson
Molnlycke Health Care
Radiation Protective Solutions
Smith & Nephew
Stratpharma
Water-Jel Technologies
3M Company

簡介目錄

Product Code: 13643

The Global Radiodermatitis Market was valued at USD 467.4 million in 2024 and is estimated to grow at a CAGR of 4.3% to reach USD 710 million by 2034. Radiodermatitis is a prevalent side effect experienced by cancer patients undergoing radiation therapy, often manifesting in localized skin changes that can significantly impact a patient's comfort and quality of life. This condition results from cumulative radiation exposure, which damages the skin's basal cell layer, impairs its regenerative ability, and triggers an inflammatory response. As oncology treatments become more advanced and radiation techniques more targeted, the frequency and visibility of radiodermatitis remain high due to the concentrated nature of doses.

In response, both healthcare providers and pharmaceutical companies are emphasizing the importance of preventative and therapeutic interventions. The increasing focus on patient-centered cancer care amplifies the need for topical treatments, advanced wound care products, and clinical guidelines tailored to mitigate radiotherapy-induced skin damage. As healthcare systems prioritize holistic approaches to oncology, the emphasis on improving patient comfort and minimizing treatment-related side effects has never been stronger. This shift toward patient-centered cancer care is driving investment into research and development of specialized topical agents and advanced wound care technologies designed specifically for radiodermatitis.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$467.4 Million
Forecast Value	$710 Million
CAGR	4.3%

The market is divided into two main segments: topical agents and dressings. The topical agents segment held a 66.5% share in 2024. Advances in the development of topical formulations, such as enhanced wound care products and more effective delivery systems, are expanding treatment options for patients. These innovations, coupled with the growing emphasis on palliative care in cancer treatment, have increased the demand for topical agents to alleviate symptoms of radiodermatitis.

The distribution of radiodermatitis treatments is also an important factor in market growth. The hospital pharmacies segment generated USD 240 million in 2024. The increasing number of cancer patients undergoing radiation therapy has contributed to a rise in the demand for radiodermatitis management products in these settings. Integration between hospital pharmacies and oncology departments ensures that patients have easy access to treatments timely, which further supports market growth.

United States Radiodermatitis Market is projected to reach USD 286 million by 2034. The U.S. has a high rate of cancer diagnoses, with a significant proportion of patients receiving radiation therapy. As a result, there is a growing demand for effective treatments to manage radiodermatitis in the country. Adopting supportive care protocols and increasing focus on skin reaction management drives the demand for these treatments. Hospitals and cancer centers across the country are placing greater emphasis on comprehensive supportive care, which includes early intervention for radiation-induced skin conditions.

Key players in the Global Radiodermatitis Market include major companies such as Coloplast, Integra Lifesciences Corporation, Johnson & Johnson, B. Braun Melsungen, and Smith & Nephew. These companies are investing in innovative products to cater to the rising demand for effective treatments. They are also strengthening their market presence by collaborating with healthcare providers and expanding their distribution channels to ensure products reach a broader patient population. To stay competitive in the radiodermatitis market, companies focus on strategic partnerships, product innovations, and expanding their global reach. Many organizations are investing in research and development to improve the efficacy of existing treatments and create new, more effective solutions for radiodermatitis management.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of cancer and radiation therapy usage
  - 3.2.1.2 Growing awareness towards skin care during radiation therapy
  - 3.2.1.3 Advancements in radiodermatitis products
  - 3.2.1.4 Favorable government initiatives and guidelines
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of advanced treatment options
  - 3.2.2.2 Lack of standardized treatment guidelines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Topical agents
- 5.2.1 Corticosteroids
- 5.2.2 Antibiotics
- 5.2.3 Creams
- 5.2.4 Other topical agents
5.3 Dressings
- 5.3.1 Hydrogel dressings
- 5.3.2 Hydrocolloid dressings
- 5.3.3 Foam dressings
- 5.3.4 Barrier films
- 5.3.5 Other dressings

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Hospital pharmacies
6.3 Retail pharmacies
6.4 E-commerce

Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE